Shunt-dependent hydrocephalus after aneurysmal subarachnoid hemorrhage

Shunt-dependent hydrocephalus (SDHC) is a known complication following aneurysmal subarachnoid hemorrhage (aSAH), but its exact prevalence and risk factors remain unclear. Prior research has identified several potential predictors, but no consensus has been reached. Some studies suggest that early radiological signs and clinical severity may be linked to SDHC, but these findings have not been consistently validated. The impact of SDHC on long-term outcomes is also debated, with conflicting reports on whether it worsens prognosis. No prior work has fully resolved the relationship between aneurysm treatment methods and the likelihood of shunt dependency. This uncertainty has limited the ability to guide clinical decisions effectively. The lack of a comprehensive synthesis of available evidence has left gaps in understanding the true burden of SDHC. This gap motivated a systematic review to clarify the prevalence, risk factors, and outcomes associated with SDHC after aSAH. The goal is to provide a clearer picture for clinicians managing these patients.

This study aimed to clarify the prevalence of shunt-dependent hydrocephalus (SDHC) after aneurysmal subarachnoid hemorrhage (aSAH). It also sought to identify the strongest predictors of SDHC and assess its impact on patient outcomes. The researchers wanted to determine whether the method of aneurysm repair influences the need for a shunt. They also aimed to compare mortality rates and clinical outcomes between patients with and without SDHC. The study was designed to address the lack of consensus in the literature and provide actionable insights for clinical practice. By pooling data from multiple studies, the authors hoped to increase the reliability of their findings. Their approach followed PRISMA guidelines to ensure methodological rigor. The ultimate goal was to offer a clearer understanding of SDHC and its implications for patient care.

The researchers conducted a systematic review following PRISMA guidelines. They searched four major databases to identify relevant studies on SDHC after aSAH. The inclusion criteria focused on studies that reported SDHC prevalence, predictors, and outcomes. They extracted data from 23 studies involving 22,264 patients. The analysis included odds ratios and confidence intervals to assess the strength of associations. They evaluated radiological and clinical factors as potential predictors. The study also compared mortality and functional outcomes between shunted and non-shunted patients. Statistical methods were used to pool results and assess heterogeneity across studies. This approach allowed the researchers to synthesize evidence from a large patient population.

The overall prevalence of SDHC was 22.3% (95% CI: 17.9–26.6%). Radiological hydrocephalus at presentation was the strongest predictor, with an odds ratio of 6.3. External ventricular drainage insertion was also a significant risk factor (OR 5.7). High Hunt and Hess scores (HHS 3–5 and 4–5) were associated with increased SDHC risk (OR 3.3 and 3.2, respectively). High Fisher grade and intraventricular blood were also significant (OR 3.1 each). Vasospasm and intraparenchymal hemorrhage were moderately predictive (OR 1.9 and 1.8). Female gender and posterior circulation aneurysms were weaker predictors (OR 1.3 and 1.4). The method of aneurysm repair did not influence shunt dependency. Patients with SDHC had a higher risk of poor clinical outcome (OR 4.3), but mortality rates were similar between groups.

The study found that SDHC occurs in 22.3% of aSAH patients. Radiological hydrocephalus at presentation is the strongest predictor. External ventricular drainage and high clinical severity scores also increase the risk. The method of aneurysm repair does not affect the likelihood of shunt dependency. SDHC is associated with a higher risk of poor clinical outcome, as measured by mRS 3–6. However, mortality rates are similar between shunted and non-shunted patients. These findings suggest that early recognition of risk factors can help guide clinical decisions. The results support the need for close monitoring of high-risk patients. The authors propose that clinicians should consider these predictors when managing aSAH patients.